Curaleaf (OTCMKTS:CURLF) Rating Lowered to Hold at Zacks Research

Curaleaf (OTCMKTS:CURLF) was downgraded by equities research analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a research note issued on Wednesday,Zacks.com reports.

Curaleaf Stock Up 6.7%

Shares of OTCMKTS CURLF opened at $3.64 on Wednesday. The firm has a market cap of $2.54 billion, a price-to-earnings ratio of -28.00 and a beta of 1.53. The company has a quick ratio of 0.74, a current ratio of 1.56 and a debt-to-equity ratio of 1.05. Curaleaf has a 52-week low of $0.72 and a 52-week high of $5.05. The business’s 50 day moving average is $3.08 and its two-hundred day moving average is $2.71.

Curaleaf (OTCMKTS:CURLF) last announced its earnings results on Tuesday, May 5th. The company reported $0.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.51. The company had revenue of $324.23 million for the quarter, compared to analyst estimates of $316.62 million. Curaleaf had a negative return on equity of 8.11% and a negative net margin of 7.76%. Research analysts predict that Curaleaf will post -0.1 EPS for the current year.

Curaleaf Company Profile

Curaleaf Holdings, Inc is a leading American cannabis company engaged in the cultivation, processing and distribution of both medical and adult-use cannabis products. Headquartered in Wakefield, Massachusetts, Curaleaf operates cultivation facilities, processing centers and retail dispensaries across multiple U.S. jurisdictions. The company’s vertically integrated model allows it to manage the entirety of its supply chain, from seed to sale, ensuring consistent quality and compliance with stringent regulatory requirements.

Curaleaf’s product portfolio spans a wide range of formats, including premium flower, vaporizer cartridges, edibles, tinctures, topicals and concentrates.